https://www.acplgroupindia.in
91

Design and development review: At suitable stages, systematic reviews of design and develo...

View more

10.As provided in the rules, surrogate marker should be considered as an interim data poin...

View more

POLICY ON NEW DRUG APPLICATION: 1. The content of New Drug Application (NDA) should be des...

View more

After the NDA is accepted the various section of the application should undergo concurrent...

View more

Such discussion to help the reviewers becomes acquainted with the information to be includ...

View more

INDUSTRY AND CDSCO COMMUNICATION 1. CDSCO needs to work collaboratively and cooperatively ...

View more

PRESENTATION AND SUBMISSION OF APPLICATION 1. In order to make regulatory review process a...

View more

3. As per the rules, for manufacture or import of new drugs, the manufacturers/ importer a...

View more

ND & CT rules recognize the consideration of surrogate endpoints for approval of new drugs...

View more

Subscribe for latest offers and updates.

we hate spam too